AMANDA MICHELE MULLINS

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family GREENEVILLE, TN NPI 1063769719

General Payments — all program years on this page

$2,555.18

  • Category: General Payments
  • Program years: PY2021–2024
  • Record count: 162
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $350.96 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $350.9620

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
ABBVIE INC. $117.777
Neurocrine BioSciences, Inc. $54.363
Novo Nordisk AS $52.113
Amgen Inc. $40.062
Indivior Inc. $33.392
USWM, LLC $21.081
Acerta Pharma LLC $18.121
Alkermes, Inc. $14.071

By program year

Program yearAmountRecords
2021 $1,000.8873
2022 $913.9447
2023 $289.4022
2024 $350.9620

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1100310747 Novo Nordisk Inc $18.34 10/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100454222 Novo Nordisk Inc $17.73 05/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100500973 Novo Nordisk Inc $16.04 02/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105619499 AstraZeneca Pharmaceuticals LP $18.12 03/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107705754 ABBVIE INC. $15.77 02/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107705756 ABBVIE INC. $17.28 03/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107705758 ABBVIE INC. $16.22 04/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107705760 ABBVIE INC. $14.61 08/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107705762 ABBVIE INC. $14.89 08/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107705764 ABBVIE INC. $19.61 09/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107705766 ABBVIE INC. $19.39 10/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117635965 Amgen Inc. $21.18 05/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117635967 Amgen Inc. $18.88 06/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1120559854 Alkermes, Inc. $14.07 07/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144564568 Indivior Inc. $16.64 07/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144564570 Indivior Inc. $16.75 09/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1150981762 Neurocrine Biosciences, Inc. $19.61 01/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1150985699 Neurocrine Biosciences, Inc. $18.84 10/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151000202 Neurocrine Biosciences, Inc. $15.91 02/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1152822465 USWM, LLC $21.08 03/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.